Merrill keeps MedImmune at neutral

MedImmune Inc. was maintained at its neutral rating by Merrill Lynch analyst Eric Ende on news the Food and Drug Administration has requested more information for the company's supplemental Biologics License Application for CAIV-T, the refrigerated version of FluMist. The analyst believes CAIV-T will be available by the 2007-2008 flu season, which means product manufacturing needs to begin by March. Merrill estimates CAIV-T sales of $163 million in 2007 and $232 million in 2008 if approval is granted in both the six-month to five-year age group and age five to 49 group. Shares of the Gaithersburg, Md.-based biotechnology company were down 8 cents, or 0.31%, at $25.86 on volume of 2,274,739 shares versus the three-month running average of 3,252,870 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.